Treatment of homologous recombination deficient cancers
AssigneeSinai Health System
InventorsDaniel Durocher, Salomé Adam, Silvia Emma Rossi, Yibo Xue
Life of this patent
Estimating the term…
Abstract
Disclosed are compounds, compositions, uses and methods using inhibitors of the CIP2A-TOPBP1 complex or agents that inhibit phosphopeptide recognition of TOPBP1 BRCT7/8, for treatment of a cancer associated with or characterized by a homologous recombination (HR) deficiency or treatment of cancer cells having HR deficiency.
Claims5
A method for inhibiting, reducing or suppressing the growth or survival of cancer cells with homologous recombination (HR) deficiencies comprising
- i) contacting the cancer cells with an effective amount of a compound or agent that reduces or inhibits phosphopeptide recognition of TOPBP1 BRCT7/8 domains, wherein the compound or agent comprises a peptide of TOPBP1 comprising residues 756 to 1000, 756 to 891, 776-851, or 830 to 851 of SEQ ID NO:
- 11, or a sequence having 95% identity thereto, and binds CIP2A or a fragment thereof;
- wherein binding of the peptide to CIP2A reduces the ability of TOPBP1 to interact with CIP2A or destabilizes or inhibits an existing CIP2A-TOPBP1 interaction, either directly or indirectly.
A method of treating a cancer associated with or characterized by a homologous recombination deficiency comprising administering to an individual in need thereof an effective amount of a CIP2A-TOPBP1 inhibitor comprising a peptide of TOPBP1 comprising residues 756 to 1000, 756 to 891, 776 to 851, or 830 to 851 of SEQ ID NO:
- 11, or a sequence having 95% identity thereto, and binds CIP2A or a fragment thereof;
- wherein binding of the peptide to CIP2A reduces the ability of TOPBP1 to interact with CIP2A or destabilizes or inhibits an existing CIP2A-TOPBP1 interaction, either directly or indirectly.
Dependencies are inferred from the claim text.